protein lipase c gamma Activation of phospholipase β by Gβγ and Gαq involves C-terminal rearrangement to release auto-inhibition Abcam ab266530-1000000Cells/vial Human PLCG1 (Phospholipase

There are several other NE inhibitors in different stages of clinical trials including alvelestat (AZD9668, COPD, phase 2, US national clinical trial number NCT03636347) (Stockley et al., 2013), BAY 85-8501 (noncystic fibrosis bronchiectasis, phase 2, NCT01818544), (Watz et al., 2019), lonodelestat (POL6014, cystic fibrosis, phase 1, NCT03748199) (Barth et al., 2020), CHF6333 (noncystic fibrosis bronchiectasis, phase 1, NCT03056326, NCT04010799) (Gramegna et al., 2017), and elafin (ARDS, phase 1, NCT02944279) (Barnes et al., 2020)

doi: 10.1038/s12276-023-01114-w 39 ChenLLinGChenKLiangRWanFZhangCet al

Under the influence of thiolase (acetyl-CoA acetyltransferase 1, ACAT1), CoA-SH is detached from one molecule of acetyl-CoA, and acetoacetyl-CoA (AcAc-CoA) is formed

In contrast, serum ELISA antibody tests detect only immune sensitization, indirect evidence that cannot confirm current or ongoing exposure, and they lack validation for exposure assessment